Prothena Corporation plc | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (37)

Latest Posts

About This Stock More About This Stock
Top Biotech Companies Are Making Progress In The Fight Against Alzheimer’s Disease
Article By: Dmitry Reykhart
Wednesday, December 21, 2022 8:40 PM EDT
The estimated cost of Alzheimer's disease and related dementia care in 2021 was $355B. Investing in the top companies that are progressing toward a treatment for Alzheimer’s can bring handsome investment returns.
In this article: LLY, RHHBY, BIIB, PRTA, VAXX
Read
Roche, Prothena Off To PhII With Their Disease-Modifying Parkinson’s Drug
Article By: Lorimer Wilson
Monday, April 3, 2017 5:41 AM EDT
Prothena turned up at the big Alzheimer’s/Parkinson’s conference in Vienna this weekend and presented early-stage data showing how its Roche-partnered drug PRX002/RG7935 can flush out toxic clusters of alpha-synuclein in Parkinson’s patients.
In this article: PRTA Also: PRAN, ACIU
Read
Prothena Announces Pricing Of Public Offering Of 2,700,000 Ordinary Shares
Article By: NASDAQ GlobeNewswire
Friday, March 3, 2017 3:15 PM EDT
Prothena Corporation plc today announced that it has sold 2,700,000 of its ordinary shares at a price to the public of $57.50 per ordinary share.
In this article: PRTA
Read
Prothena - Chart Of The Day
Article By: Jim Van Meerten
Thursday, July 16, 2015 8:33 PM EDT
Since the Trend Spotter signaled a buy on 5/29 the stock gained 48.38%.
In this article: PRTA
Read
5 Stocks Leading XBI Biotech ETF Higher
Article By: Sweta Killa
Friday, June 26, 2015 6:51 AM EDT
With an AUM of $2.3 billion and average daily volume of close to a million shares, XBI is extremely liquid and an easily traded fund. It provides equal weight exposure across 106 stocks by tracking the S&P Biotechnology Select Industry Index.
In this article: XBI, EGRX, HRTX, EXEL, RTRX, PRTA
Read

Latest Tweets for $PRTA

No tweets yet!

PARTNER HEADLINES